Atossa Therapeutics Valuation
Is ATOS * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ATOS * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ATOS *'s fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ATOS *'s fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ATOS *?
Key metric: As ATOS * is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is ATOS *'s PB Ratio? | |
|---|---|
| PB Ratio | 2.2x |
| Book | US$73.68m |
| Market Cap | US$161.03m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -2.9x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does ATOS *'s PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.6x | ||
1167 Jacobio Pharmaceuticals Group | 1.2x | n/a | HK$1.2b |
688217 Shanghai Rightongene Biotechnology | 1.2x | 62.5% | CN¥1.2b |
TIL Instil Bio | 1.1x | 53.9% | US$193.8m |
GOSS Gossamer Bio | 2.9x | 18.8% | US$159.0m |
ATOS * Atossa Therapeutics | 2.2x | 40.9% | Mex$161.0m |
Price-To-Book vs Peers: ATOS * is expensive based on its Price-To-Book Ratio (2.2x) compared to the peer average (1.6x).
Price to Book Ratio vs Industry
How does ATOS *'s PB Ratio compare vs other companies in the Global Biotechs Industry?
| 86 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 86 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: ATOS * is good value based on its Price-To-Book Ratio (2.2x) compared to the Global Biotechs industry average (2.4x).
Price to Book Ratio vs Fair Ratio
What is ATOS *'s PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 2.2x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate ATOS *'s Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | Mex$27.00 | Mex$119.76 +343.6% | 22.5% | Mex$143.72 | Mex$82.12 | n/a | 3 |
| Nov ’25 | Mex$28.50 | Mex$110.09 +286.3% | 19.6% | Mex$130.10 | Mex$80.06 | n/a | 3 |
| Oct ’25 | Mex$28.91 | Mex$108.84 +276.5% | 19.6% | Mex$128.63 | Mex$79.16 | n/a | 3 |
| Sep ’25 | Mex$27.50 | Mex$103.37 +275.9% | 18.6% | Mex$119.27 | Mex$76.33 | n/a | 3 |
| Aug ’25 | Mex$25.00 | Mex$96.86 +287.4% | 18.6% | Mex$111.76 | Mex$71.53 | n/a | 3 |
| Jul ’25 | Mex$22.54 | Mex$96.86 +329.7% | 18.6% | Mex$111.76 | Mex$71.53 | n/a | 3 |
| Jun ’25 | Mex$22.50 | Mex$89.66 +298.5% | 17.7% | Mex$100.87 | Mex$67.25 | n/a | 3 |
| May ’25 | Mex$26.25 | Mex$79.42 +202.5% | 20.2% | Mex$102.11 | Mex$68.07 | n/a | 3 |
| Apr ’25 | Mex$33.47 | Mex$78.25 +133.8% | 18.0% | Mex$98.17 | Mex$68.29 | n/a | 3 |
| Mar ’25 | Mex$18.00 | Mex$78.25 +334.7% | 18.0% | Mex$98.17 | Mex$68.29 | n/a | 3 |
| Feb ’25 | Mex$15.00 | Mex$82.82 +452.1% | 17.9% | Mex$97.68 | Mex$67.95 | n/a | 2 |
| Jan ’25 | Mex$14.41 | Mex$82.82 +474.7% | 17.9% | Mex$97.68 | Mex$67.95 | n/a | 2 |
| Dec ’24 | Mex$13.00 | Mex$82.42 +534.0% | 15.8% | Mex$95.43 | Mex$69.41 | n/a | 2 |
| Nov ’24 | Mex$12.50 | Mex$85.13 +581.0% | 12.9% | Mex$96.87 | Mex$70.45 | Mex$28.50 | 3 |
| Oct ’24 | Mex$14.00 | Mex$85.13 +508.1% | 12.9% | Mex$96.87 | Mex$70.45 | Mex$28.91 | 3 |
| Sep ’24 | Mex$14.00 | Mex$83.15 +493.9% | 13.5% | Mex$94.38 | Mex$71.91 | Mex$27.50 | 2 |
| Aug ’24 | Mex$19.00 | Mex$83.15 +337.6% | 13.5% | Mex$94.38 | Mex$71.91 | Mex$25.00 | 2 |
| Jul ’24 | Mex$21.74 | Mex$83.15 +282.5% | 13.5% | Mex$94.38 | Mex$71.91 | Mex$22.54 | 2 |
| Jun ’24 | Mex$16.50 | Mex$83.15 +403.9% | 13.5% | Mex$94.38 | Mex$71.91 | Mex$22.50 | 2 |
| May ’24 | Mex$11.95 | Mex$86.58 +624.5% | 15.8% | Mex$100.25 | Mex$72.91 | Mex$26.25 | 2 |
| Apr ’24 | Mex$12.80 | Mex$86.58 +576.4% | 15.8% | Mex$100.25 | Mex$72.91 | Mex$33.47 | 2 |
| Mar ’24 | Mex$14.25 | Mex$91.83 +544.4% | 20.0% | Mex$110.19 | Mex$73.46 | Mex$18.00 | 2 |
| Feb ’24 | Mex$16.00 | Mex$97.50 +509.4% | 20.0% | Mex$117.00 | Mex$78.00 | Mex$15.00 | 2 |
| Jan ’24 | Mex$10.21 | Mex$97.50 +855.0% | 20.0% | Mex$117.00 | Mex$78.00 | Mex$14.41 | 2 |
| Dec ’23 | Mex$14.00 | Mex$97.50 +596.5% | 20.0% | Mex$117.00 | Mex$78.00 | Mex$13.00 | 2 |
| Nov ’23 | Mex$19.00 | Mex$109.93 +478.6% | 27.3% | Mex$139.91 | Mex$79.95 | Mex$12.50 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
IQVIA Holdings
US$36.6b
Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
IQV *
US$3,880.00
7D
0%
1Y
6.3%
CSPC Pharmaceutical Group
HK$69.4b
An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally.
1093 N
HK$15.69
7D
0%
1Y
-27.0%
Exact Sciences
US$13.1b
Provides cancer screening and diagnostic test products in the United States and internationally.
EXAS *
US$872.00
7D
0%
1Y
n/a